In the news
Takara Bio USA, Inc. (formerly Clontech Laboratories, Inc.), a wholly owned subsidiary of Takara Bio Inc., develops, manufactures, and distributes a wide range of life science research reagents under the Takara, Clontech, and Cellartis brands. To keep you up to date with the latest happenings at Takara Bio USA, we have compiled our recent announcements and press releases below.
Clontech Laboratories, Inc. to release a highly sensitive kit for human T-cell receptor repertoire analysis
Date: January 20, 2016
Categories: Press release
Mountain View, CA—January 20, 2016—Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the upcoming launch of the SMARTer Human TCR a/b Profiling Kit. This system leverages SMART technology and employs a 5' RACE-like approach to capture complete V(D)J variable regions of TCR transcripts, enabling users to analyze T-cell receptor (TCR) diversity from human RNA samples or directly from cells.
Clontech Laboratories, Inc. releases a new powerful delivery technology for CRISPR/Cas9-mediated gene editing
Date: January 11, 2016
Categories: Press release
Mountain View, CA—January 11, 2016—Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the launch of the Guide-it CRISPR/Cas9 Gesicle Production System. This system provides an innovative method to deliver Cas9/single guide RNA (sgRNA) ribonucleoprotein complexes to a broad range of cell types.
Clontech Laboratories, Inc. earns ISO 13485:2003 certification
Date: December 14, 2015
Categories: Press release
Mountain View, CA—December 14, 2015—Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc. and provider of innovative reagents and kits for the life sciences, announced today that it has earned ISO 13485:2003 certification, an internationally-recognized quality standard for medical devices and related services.
Takara Bio Europe AB to launch Cellartis iPS Cell to Hepatocyte Differentiation System
Date: November 16, 2015
Categories: Press release
Göteborg, Sweden, November 16, 2015, Takara Bio Europe AB, a wholly-owned subsidiary of Takara Bio Inc., announced today that it is launching the Cellartis iPS Cell to Hepatocyte Differentiation System and related ancillary products. This system provides a complete solution for directed differentiation of disease-specific or patient-specific human inducible pluripotent stem (hiPS) cells to hepatocytes by combining a standardized protocol and optimized, ready-to-use media and coating reagents.
Takara Bio Europe releases an innovative iPS cell culture medium for pre-clinical use: Cellartis DEF-CS Xeno-Free Culture Medium
Date: June 1, 2015
Categories: Press release
Göteborg, Sweden, June 1, 2015, Takara Bio Europe AB, formerly Cellartis AB, a wholly-owned subsidiary of Takara Bio Inc., announced today that it is launching an advanced cell culture system for iPS cell culture. This chemically-defined culture system is pre-clinical grade, free from human- and animal-derived components, and designed for efficient expansion of undifferentiated human iPS cells.
Clontech Laboratories, Inc. signs agreement with Ludwig Cancer Research for access to Smart-seq2
Date: March 23, 2015
Categories: Press release
Mountain View, CA—March 23, 2015—Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced that it has entered into an exclusive agreement with Ludwig Cancer Research for rights to the Smart-seq2 method for single-cell RNA-seq, which was developed in Rickard Sandberg’s laboratory at Ludwig Stockholm. As a result of this agreement, Clontech will become the exclusive supplier of SMART-Seq2 technology.
Clontech Laboratories, Inc. licenses CRISPR/Cas9 technology from the Broad Institute
Date: October 27, 2014
Categories: Press release
Mountain View, CA—October 27, 2014—Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced that they have entered into a non-exclusive license agreement with the Broad Institute to access intellectual property related to the CRISPR/Cas9 gene editing system.
Clontech Laboratories, Inc. releases the DNA SMART ChIP-Seq Kit
Date: September 22, 2014
Categories: Press release
Mountain View, CA—September 22, 2014—Clontech Laboratories, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the DNA SMART ChIP-Seq Kit. This kit adapts Clontech's patented SMART technology in an innovative manner for use with low-input samples, including both dsDNA and ssDNA templates, to generate ChIP-seq libraries for NGS.
Announcement—Clontech Laboratories, Inc. partners with Flash Therapeutics SAS to provide highly concentrated purified lentiviral particles
Date: May 5, 2014
Categories: Press release
Mountain View, CA—May 5, 2014—Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced that it has partnered with Flash Therapeutics SAS to combine Clontech's Living Colors fluorescent protein and Tet-On 3G technologies with Flash Therapeutics' expertise in providing the highest quality ready-to-use lentiviral particles as vectors for gene delivery.
Announcement—Clontech Laboratories, Inc. releases the SMARTer Stranded RNA-Seq Kit
Date: October 21, 2013
Categories: Press release
Mountain View, CA—October 21, 2013—Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the launch of the SMARTer Stranded RNA-Seq Kit for strand-specific RNA-Seq from low-input RNA samples. This kit integrates Illumina library preparation with SMART cDNA amplification to create indexed libraries in less than four hours and provides high-quality stranded data, with greater than 99% accuracy in strand identification.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2025 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.
